IMMUNOCORE HOLDINGS PL

The UK Medicines and Healthcare products Regulatory Agency (MHRA), Australian Therapeutic Goods Administration (TGA) and Health Canada approve KIMMTRAK® (tebentafusp) for the treatment of unresectable or metastatic uveal melanoma

08 Jun 2022 07:00:00 By Nasdaq GlobeNewswire

Immunocore presents new data on KIMMTRAK (tebentafusp-tebn) in metastatic cutaneous (mCM) and uveal melanoma (mUM) at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting

06 Jun 2022 07:00:00 By Nasdaq GlobeNewswire

Immunocore announces clinical trial collaboration with Sanofi to evaluate Sanofi’s product candidate SAR444245, non-alpha IL-2, in combination with KIMMTRAK® in patients with metastatic cutaneous melanoma

03 Jun 2022 07:00:00 By Nasdaq GlobeNewswire

Immunocore to present at upcoming investor conferences

01 Jun 2022 16:30:00 By Nasdaq GlobeNewswire

Immunocore announces upcoming presentations at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting

26 May 2022 18:00:00 By Nasdaq GlobeNewswire

Immunocore Reports First Quarter 2022 Financial Results and Provides Business Update

11 May 2022 07:00:00 By Nasdaq GlobeNewswire

Immunocore to present at the 21st Annual Needham Healthcare Conference

07 Apr 2022 07:00:00 By Nasdaq GlobeNewswire

European Commission Approves KIMMTRAK® (tebentafusp) for the treatment of unresectable or metastatic uveal melanoma

04 Apr 2022 07:00:00 By Nasdaq GlobeNewswire

Immunocore to present at Oppenheimer’s 32nd Annual Healthcare Conference

09 Mar 2022 17:30:00 By Nasdaq GlobeNewswire

Immunocore Reports Full Year 2021 Financial Results and Provides Business Update

03 Mar 2022 07:00:00 By Nasdaq GlobeNewswire

Immunocore receives positive CHMP opinion for KIMMTRAK® (tebentafusp) for the treatment of unresectable or metastatic uveal melanoma

25 Feb 2022 02:00:00 By Nasdaq GlobeNewswire

Immunocore to present at the SVB Leerink Global Healthcare Conference

11 Feb 2022 07:00:00 By Nasdaq GlobeNewswire

Immunocore announces FDA approval of KIMMTRAK® (tebentafusp-tebn) for the treatment of unresectable or metastatic uveal melanoma

26 Jan 2022 07:00:00 By Nasdaq GlobeNewswire

Immunocore to present at the 40th Annual J.P. Morgan Healthcare Conference

06 Jan 2022 07:00:00 By Nasdaq GlobeNewswire

Immunocore announces initial Phase 1 data of ImmTAC® candidate IMC-C103C targeting MAGE-A4

06 Dec 2021 07:00:00 By Nasdaq GlobeNewswire

Immunocore to present at the Jefferies London Healthcare Conference

11 Nov 2021 07:00:00 By Nasdaq GlobeNewswire

Immunocore Reports Third Quarter 2021 Financial Results and Provides Business Update

10 Nov 2021 07:00:00 By Nasdaq GlobeNewswire

Immunocore presents new data on tebentafusp in metastatic cutaneous melanoma (mCM) and uveal melanoma (mUM) at the Society for Immunotherapy of Cancer (SITC) 36th Annual Meeting

09 Nov 2021 08:01:00 By Nasdaq GlobeNewswire

Immunocore and Medison Pharma Partner for Future Commercialization of Tebentafusp in Canada, Central Eastern Europe, and Israel

18 Oct 2021 07:30:00 By Nasdaq GlobeNewswire

Immunocore announces publication of phase 3 data comparing tebentafusp with investigator’s choice in The New England Journal of Medicine

22 Sep 2021 18:00:00 By Nasdaq GlobeNewswire